Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
|Videos|March 15, 2011
Dr. Tripathy on Bone Health in Breast Cancer Patients
Author(s)Debu Tripathy, MD,
Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.
Advertisement
Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.
Advertisement
Related to this article
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5